Trial Information
Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93)
Inclusion Criteria:
- Acute Lymphocytic Leukemia
- Age 15 - 65 years
Exclusion Criteria:
- Serious secondary diseases which may compromise intensified chemotherapeutical
treatment
- Serious psychiatric diseases, which may compromise compliance with therapy
- HIV-1 or HIV-2 Infection
- Pretreatment > 2 weeks or chemotherapy other than Vincristine and Steroids
- Patients without central diagnosis who cannot be allocated to a risk group
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
remission rate, disease free survival, overall survival
Principal Investigator
Dieter Hoelzer, MD, PhD
Investigator Role:
Study Chair
Investigator Affiliation:
University of Frankfurt, Medical Department II
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
GMALL09
NCT ID:
NCT00199069
Start Date:
April 1993
Completion Date:
Related Keywords:
- Adult Acute Lymphocytic Leukemia
- ALL
- Treatment
- De Novo
- Adult
- Leukemia
- Leukemia, Lymphoid
- Precursor Cell Lymphoblastic Leukemia-Lymphoma